Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 2, 1999, Pages 612-617

  Lark, Michael W ^a   Stroup, George B ^a   Hwang, Shing Mei ^a   James, Ian E ^a   Rieman, David J ^a   Drake, Fred H ^a   Bradbeer, Jeremy N ^a   Mathur, Ashwini ^a   Erhard, Karl F ^a   Newlander, Kenneth A ^a   Ross, Stephen T ^a   Salyers, Kevin L ^a   Smith, Brian R ^a   Miller, William H ^a   Huffman, William F ^a   Gowen, Maxine ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 DIHYDRO 3 [3 (2 PYRIDINYLAMINO)PROPOXY] 5H DIBENZO[A,D]CYCLOHEPTENE 10 ACETIC ACID; ARGINYLLYSYLASPARTIC ACID; BLOCKING AGENT; SB 223245; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ACETIC ACIDS; ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; BONE RESORPTION; CELL ADHESION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTEGRINS; OSTEOPOROSIS; OVARIECTOMY; PARATHYROIDECTOMY; PLATELET AGGREGATION; PROTEIN BINDING; RATS; RECEPTORS, VITRONECTIN; THYROIDECTOMY; TIME FACTORS;

EID: 0032722766     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Baron, RE (1996) in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 3rd ed., J. B. Lippincott, Philadelphia.
2. Carney S and Thompson L (1982) Effect of differing concentrations of parathyroid hormone on rat renal electrolyte excretion. Am J Physiol 243:F514-F517.
3. Clover J, Dodds RA and Gowen M (1992) Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. J Cell Sci 103:267-271.
4. Crippes BA, Engleman VW, Settle SL, Delarco J, Ornberg RL, Helfrich MH, Horton MA and Nickols GA (1996) Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology 137:918-924.
5. Davies J, Warwick J, Totty N, Philip R, Helfrich M and Horton M (1989) The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 109:1817-1826.
6. Dunnett CW (1965) A multiple comparisons procedure comparing several treatments with a control. J Am Stat Assoc 55:1096-1121.
7. Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG and Teitelbaum SL (1997) A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 99:2284-2292.
8. Fisher JE, Caalfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA and Rosenblatt M (1993) Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein. Endocrinology 132:1411-1413.
9. Foged NT, Delaisse J-M, Hou P, Lou H, Sato T, Winding B and Bonde M (1996) Quantification of the collagenolytic activity of isolated osteoclasts by enzymelinked immunosorbent assay. J Bone Miner Res 11:226-237.
10. Helfrich MH, Nesbitt SA and Horton MA (1992) Integrins on rat osteoclasts: Characterization of two monoclonal antibodies (F4 and F11) to rat beta 3. J Bone Miner Res 7:345-351.
11. Horton MA, Taylor, ML, Arnett TR and Helfrich MH (1991) Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp Cell Res 195:368-375.
12. Inoue M, Teitelbaum SL, Hurter L, Hruska K, Seftor E, Hendrix M and Ross FP (1995) GM-CSF regulates expression of the functional integrins alpha(V)beta(3) and alpha(V)beta(5) in a reciprocal manner during osteoclastogenesis (Abstract). J Bone Miner Res 10:S163a.
13. James IE, Lark MW, Zembryki D, Lee-Rykaczewski EV, Hwang SM, Tomaszek TA, Belfiore P and Gowen M (1999) Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antresorptive agents. J Bone Miner Res 14:1562-1569.
14. James IE, Dodds RA, Olivera DL, Nuttall ME and Gowen M (1996) Human osteoclastoma-derived stromal cells: Correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J Bone Miner Res 11:1453-1460.
15. Keenan RM, Miller WH, Kwon C, Ali FE, Callahan JF, Calvo RR, Hwang S-M, Kopple KD, Peishoff CE, Samanen JM, Wong AS, Yuan CK and Huffman WF (1997) Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists. J Med Chem 40:2289-2292.
16. Kumar CS, James IE, Wong A, Mwangi V, Field JA, Nuthulaganti P, Connor JR, Eichman, C, Ali F, Hwang S-M, Rieman DJ, Drake FH and Gowen M (1997) Cloning and characterization of a novel integrin beta3 subunit. J Biol Chem 272:16390-16397.
17. McHugh KP, Hodivala-Dilke K, Cheng S-L, Zheng MH, Aviola LV, Hynes RO, Ross FP and Teitelbaum SL (1998) The β3 knockout mouse is osteosclerotic and has dysfunctional osteoblasts. Bone 23:S109.
18. Miller WH, Bondinell WE, Cousins RD, Erhard KF, Jakas DR, Keenan RM, Ku KW, Newlander KA, Ross ST, Haltiwanger RC, Bradbeer J, Drake FH, Gowen M, Hoffman SJ, Hwang SM, James IE, Lark MW, Lechowska B, Rieman DJ, Stroup GB, Vasko-Moser JA, Zembryki DL, Azzarano LM, Adams PC, Salyers KL, Smith BR, Ward KW, Johanson KO and Huffman WF (1999) Highly orally bioavailable nonpeptide vitronectin receprtor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett 9:1807-1812.
19. Milliken GA and Johnson DE (1984) Analysis of Messy Data, vol 1, Van Nostrand Reinhold, New York.
20. Nesbitt S, Nesbit A, Helfrich, M and Horton M (1993) Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins. J Biol Chem 268:16737-16745.
21. Nichols AJ, Vasko JA, Valocik RE, Kopaciewicz LJ, Storer BL, Ali FE, Romoff T, Calvo R and Samanen JM (1994) The in vitro pharmacological profile of SK&F 106760, a novel GPIIB/IIIA antagonist. Thromb Res 75:143-156.
22. Reeve J (1996) PTH: A future role in the management of osteoporosis? J Bone Miner Res 11:440-445.
23. Shinar DM, Schmidt A, Halperin D, Rodan GA and Weinreb M (1993) Expression of alpha v and beta 3 integrin subunits in rat osteoclasts in situ. J Bone Miner Res 8:403-414.
24. Teitelbaum SL, Tondravi MM and Ross FP (1997) Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. J Leuk 61:381-388.
25. Westfall PH and Young SS (1993) Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment, John Wiley & Sons, New York.
26. 3H]SK&F-107260 binding assay. Mol Pharmacol 50:529-537.
27. Yamamoto M, Balena R, Markatos A, Gentile M, Garsky VM and Rodan GA (1993) Direct demonstration of inhibitory effect of Echistatin on PTH-induced bone resorption in vivo in mice (Abstract). J Bone Miner Res 8:123a.
28. Yamamoto M, Fisher JE, Gentile M, Seedor JG, Leu C-T, Rodan SB and Rodan GA (1997) The integrin ligand Echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 139:1411-1419.